Fulcrum Therapeutics, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsFulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on genetically defined rare diseases, now undergoing a strategic review after discontinuing its lead program.
What they do
Fulcrum historically developed small molecules for rare diseases, with its lead candidate pociredir aimed at treating sickle cell disease (SCD). Following FDA concerns and program discontinuation, the company has ceased R&D activities, reduced its workforce by ~85%, and is exploring strategic alternatives including a possible sale, merger, or liquidation.
Revenue drivers
- None (no product revenue) — Fulcrum has never generated product revenue; historical revenue came from collaboration and license agreements (e.g., $80.0M in 2024, but $0 in 2025).
Recent performance
In Q2 2026, Fulcrum reported a net loss of $45.1M for the six months ended June 30, 2026, versus $35.0M in the prior-year period. As of June 30, 2026, the company had $318.8M in cash, cash equivalents, and marketable securities, and an accumulated deficit of $639.3M. Full-year 2025 net loss was $74.9M on zero revenue, compared to a $9.7M net loss in 2024 which included $80.0M in collaboration revenue.
Strategy
Management has initiated a comprehensive review of strategic alternatives to maximize stockholder value, engaging Leerink Partners LLC as financial advisor. The board approved a restructuring that reduced headcount from 57 to 9 full-time employees, ceased R&D, and is seeking to exit its leased facility. If no strategic transaction is completed, the board may pursue dissolution and liquidation.
Risks
- Program discontinuation — Pociredir development was halted in June 2026 after FDA feedback indicated a non-viable benefit-risk profile, eliminating the company's primary value driver.
- Strategic review uncertainty — There is no assurance that the review will result in any transaction; failure to find a buyer or partner could lead to dissolution and liquidation.
- Cash burn and limited runway — Despite $318.8M in cash, ongoing advisory and restructuring costs will consume capital, and without new revenue the company remains dependent on a strategic deal.
- No product revenue — The company has never generated product sales and does not expect to unless it resumes R&D, leaving no recurring income source.
Outlook
Fulcrum expects operating expenses to decrease substantially after the restructuring, but will incur restructuring charges, impairment costs, and professional fees related to the strategic review. Management believes existing cash funds operations for at least the next 12 months. No timeline has been set for completing the strategic review, and the outcome remains uncertain.